HCC—subtypes, stratification and sorafenib
نویسندگان
چکیده
منابع مشابه
Sorafenib and sunitinib.
Sorafenib (Nexavar ; Bayer Pharmaceuticals, West Haven, CT) (Fig. 1A) and sunitinib (Sutent ; Pfizer Inc., New York, NY) (Fig. 1B) are orally bioavailable, small molecule inhibitors of multiple intracellular and receptor protein kinases that are components of signaling pathways that control tumor growth and angiogenesis. These agents have similar drug profiles and overlapping targets, which are...
متن کاملBiomarkers and Personalized Sorafenib Therapy
Compared with other types of cancer, hepatocellular carcinoma (HCC) is highly heterogeneous because of the intrinsic diversity in its pathogenesis, molecular heterogeneity, its multicentric occurrence, and its etiology, among others. Until now, locoregional therapies such as resection, ablation, and transarterial chemoembolization (TACE) have been performed extensively to treat HCC because the ...
متن کاملEffect of curcumin and sorafenib on AKT gene expression in KG1 and U937 cell lines
Abstract Background and Objectives Acute myeloid leukemia is a heterozygous hematologic malignancy that is manifested by the accumulation of hematopoietics stem cells in peripheral blood and bone marrow. Anticancer effects and cryotoxic activity of curcumin have been proven frequently in many cancers. Sorafenib is known as an inhibitor of angiogenesis which prevent cells’ survival. In the...
متن کاملBiomarkers and Personalized Sorafenib Therapy
Compared with other types of cancer, hepatocellular carcinoma (HCC) is highly heterogeneous because of the intrinsic diversity in its pathogenesis, molecular heterogeneity, its multicentric occurrence, and its etiology, among others. Until now, locoregional therapies such as resection, ablation, and transarterial chemoembolization (TACE) have been performed extensively to treat HCC because the ...
متن کاملCancer Therapy: Preclinical Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Purpose:Many tyrosine kinase inhibitors (TKI) undergo extensive hepaticmetabolism, butmechanisms of their hepatocellular uptake remain poorly understood. We hypothesized that liver uptake of TKIs is mediated by the solute carriers OATP1B1 and OATP1B3. Experimental Design: Transport of crizotinib, dasatinib, gefitinib, imatinib, nilotinib, pazopanib, sorafenib, sunitinib, vandetanib, and vemuraf...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Gastroenterology & Hepatology
سال: 2014
ISSN: 1759-5045,1759-5053
DOI: 10.1038/nrgastro.2014.157